SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 5,418.89 |
| Enterprise Value ($M) | 5,527.02 |
| Book Value ($M) | 5,119.41 |
| Book Value / Share | 34.11 |
| Price / Book | 1.06 |
| NCAV ($M) | -867.04 |
| NCAV / Share | -5.78 |
| Price / NCAV | -6.25 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.12 |
| Return on Assets (ROA) | 0.11 |
| Return on Equity (ROE) | 0.15 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.13 |
| Current Ratio | 1.13 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 735.07 |
| Assets | 6,721.52 |
| Liabilities | 1,602.11 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 1,201.77 |
| Operating Income | 940.15 |
| Net Income | 688.07 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 686.26 |
| Cash from Investing | -320.51 |
| Cash from Financing | -382.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Genworth Holdings, Inc. | 81.00 | -4.77 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 51,920 | 323,751 | 16.04 | |
| 61,686 | 401,894 | 15.35 | |
| 49,199 | 308,325 | 15.96 | |
| 69,823 | 394,413 | 17.70 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ACAD – ACADIA Pharmaceuticals Inc. | ACLX – Arcellx, Inc. |
| ACRS – Aclaris Therapeutics, Inc. | ADPT – Adaptive Biotechnologies Corporation |
| AGIO – Agios Pharmaceuticals, Inc. |
Financial data and stock pages provided by
Fintel.io